This retrospective study was performed at the Department of Oncology, Istanbul
University Institute of Oncology. The inclusion criteria were an age of ≥65
years, diagnosis of soft tissue sarcoma, and follow-up or treatment for soft
tissue sarcoma. Patients aged <65 years, patients with bone and cartilage
tumors, and patients who had discontinued follow-up were not included in the
study. The files of patients from January 2000 to December 2020 were examined,
and patients who were deemed suitable for the study were included.
University Institute of Oncology. The inclusion criteria were an age of ≥65
years, diagnosis of soft tissue sarcoma, and follow-up or treatment for soft
tissue sarcoma. Patients aged <65 years, patients with bone and cartilage
tumors, and patients who had discontinued follow-up were not included in the
study. The files of patients from January 2000 to December 2020 were examined,
and patients who were deemed suitable for the study were included.
